EG 427
EG 427 develops HSV-1-based vectors by exploiting the natural properties of Herpes Simplex Virus 1 (HSV-1) and its ability to establish lifelong latency in peripheral neurons to ensure highly specific and durable expression of transgenes to treat patients with severe, chronic and localized diseases, enabling physicians to cure neurogenic bladder disorders post a spinal cord injury.
$28.25M
Latest Funding
Series B
Latest Funding Stage
2025-02-20
Funding Date
€49 million
Total Funding
24
Employees
France
Location
Paris, Ile-de-France
City & State
Sales-Ready Summary
EG427 recently raised $28.25M in Series B funding and utilizes a tech stack including PHP and Nginx, suggesting potential opportunities for vendors offering development tools, server solutions, or security enhancements.
Key Contacts
Open Positions
View Careers PageHiring For
Similar Startups
Eikon Therapeutics
Eikon Therapeutics is a biopharmaceutical company that focuses on developing innovative technologies for drug discovery. The company utilizes advanced live-cell resolution microscopy and engineering to identify and create new therapeutic candidates. Eikon Therapeutics aims to enhance the understanding of biological processes at a cellular level,supporting targeted treatment development.
Arsenale Bioyards
Arsenale is transforming biomanufacturing with a proprietary end-to-end platform that integrates advanced hardware, AI-driven software, and precision fermentation. Designed to bridge the gap from lab-scale innovation to industrial-scale production, Arsenale enables industries like food, chemicals, and materials to seamlessly develop and scalebio-based alternatives to petrochemicals and animal-derived products.
Avitia
Avitia improves cancer treatment via advanced molecular testing solutions. Avitia offer testing tools for use on-site, bioinformatics driven by AI, and actionable insights aimed at enhancing patient outcomes. Avitia offerings comprise pre-prepared NGS panels, simplified reporting mechanisms, and cooperative diagnostic platforms.
Ignota Labs
Ignota Labs recognizes that safety errors during the drug discovery process can result in expensive setbacks and delays in bringing life-changing medications to market. Ignota Labs world leading AI methods, which include deep learning and machine learning approaches, are intended to examine complicated molecular data and provide accurate toxicitypredictions.